Anaplastic thyroid carcinoma: Current treatments and potential new therapeutic options with emphasis on TfR1/CD71

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Parenti, Rosalba ^a   Salvatorelli, Lucia ^a   Magro, Gaetano ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE ANTIBODY; B RAF KINASE INHIBITOR; BETA CATENIN; CD71 ANTIGEN; ENZYME ANTIBODY; GALLIUM NITRATE; MICRORNA 125B; MICRORNA 26A; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD71; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER PROGNOSIS; CARCINOGENESIS; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC MARKER; HUMAN; MISSENSE MUTATION; MOLECULAR DYNAMICS; MORPHOLOGY; NONHUMAN; ONCOGENE RAS; PIK3CA GENE; PROTEIN EXPRESSION; REVIEW; RNA ANALYSIS; THYROID CARCINOMA; TUMOR DIFFERENTIATION; TUMOR GENE; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84904677412     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/685396     Document Type: Review

References (116)

1. Enewold L., Zhu K., Ron E., Marrogi A. J., Stojadinovic A., Peoples G. E., Devesa S. S., Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiology Biomarkers and Prevention 2009 18 3 784 791 10.1158/1055-9965.EPI-08-0960 2-s2.0-64549114616
2. Patel K. N., Shaha A. R., Poorly differentiated and anaplastic thyroid cancer. Cancer Control 2006 13 2 119 128 2-s2.0-33745199172
3. Cornett W. R., Sharma A. K., Day T. A., Anaplastic thyroid carcinoma: an overview. Current Oncology Reports 2007 9 2 152 158 (Pubitemid 46332389)
4. Wein R. O., Weber R. S., Anaplastic thyroid carcinoma: palliation or treatment? Current Opinion in Otolaryngology and Head and Neck Surgery 2011 19 2 113 118 10.1097/MOO.0b013e328343af3d 2-s2.0-79953865811
5. Spires J. R., Schwartz M. R., Miller R. H., Anaplastic thyroid carcinoma. Association with differentiated thyroid cancer. Archives of Otolaryngology-Head and Neck Surgery 1988 114 1 40 44 10.1001/archotol.1988.01860130044012 2-s2.0-0023878428 (Pubitemid 18031595)
6. Lo C., Lam K., Wan K., Anaplastic carcinoma of the thyroid. The American Journal of Surgery 1999 177 4 337 339 10.1016/S0002-9610(99)00052-5 2-s2.0-0032916622 (Pubitemid 29218347)
7. Haigh P. I., Ituarte P. H., Wu H. S., Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001 15 91(12) 2335 2342 (Pubitemid 32552820)
8. McIver B., Hay I. D., Giuffrida D. F., Dvorak C. E., Grant C. S., Thompson G. B., Van Heerden J. A., Goellner J. R., Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001 130 6 1028 1034 10.1067/msy.2001.118266 2-s2.0-0035666788 (Pubitemid 34014569)
9. Sugitani I., Kasai N., Fujimoto Y., Yanagisawa A., Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World Journal of Surgery 2001 25 5 617 622 10.1007/s002680020166 2-s2.0-0035039591 (Pubitemid 32441436)
10. Aldinger K. A., Samaan N. A., Ibanez M., Stratton Hill C. Jr., Anaplastic carcinoma of the thyroid. A review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 1978 41 6 2267 2275 10.1002/1097-0142(197806) 41:6<2267::AID-CNCR2820410627>3.0.CO;2-7 2-s2.0-0018179367 (Pubitemid 8370197)
11. Demeter J. G., De Jong S. A., Lawrence A. M., Paloyan E., Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 1991 110 6 956 963 2-s2.0-0026327082
12. Venkatesh Y. S., Ordonez N. G., Schultz P. N., Hickey R. C., Goepfert H., Samaan N. A., Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990 66 2 321 330 (Pubitemid 20205915)
13. Nilsson O., Lindeberg J., Zedenius J., Ekman E., Tennvall J., Blomgren H., Grimelius L., Lundell G., Wallin G., Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World Journal of Surgery 1998 22 7 725 730 10.1007/s002689900460 2-s2.0-0031863942 (Pubitemid 28277869)
14. Voutilainen P. E., Multanen M., Haapiainen R. K., Leppäniemi A. K., Sivula A. H., Anaplastic thyroid carcinoma survival. World Journal of Surgery 1999 23 9 975 979 10.1007/s002689900610 2-s2.0-0032807229 (Pubitemid 29398484)
15. Pierie J.-P. E. N., Muzikansky A., Gaz R. D., Faquin W. C., Ott M. J., The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Annals of Surgical Oncology 2002 9 1 57 64 10.1245/aso.2002.9.1.57 2-s2.0-0036205085 (Pubitemid 34262898)
16. Ordonez N., Baloch Z., Matias-Guiu X., De Lellis R. A., Lloyd R. V., Heitz P. U., Eng C., Undifferentiated (anaplastic) carcinoma. Pathology and Genetics-Tumor of Endocrine Organs 2004 WHO 77 80
17. Regalbuto C., Frasca F., Pellegriti G., Malandrino P., Marturano I., Di Carlo I., Pezzino V., Update on thyroid cancer treatment. Future Oncology 2012 8 10 1331 1348 10.2217/fon.12.123 2-s2.0-84868537517
18. Salvatore G., Nappi T. C., Salerno P., Jiang Y., Garbi C., Ugolini C., Miccoli P., Basolo F., Castellone M. D., Cirafici A. M., Melillo R. M., Fusco A., Bittner M. L., Santoro M., A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Research 2007 67 21 10148 10158 10.1158/0008-5472.CAN-07-1887 2-s2.0-35948980377 (Pubitemid 350070786)
19. Sanders E. M. Jr., LiVolsi V. A., Brierley J., Shin J., Randolph G. W., An evidence-based review of poorly differentiated thyroid cancer. World Journal of Surgery 2007 31 5 934 945 10.1007/s00268-007-9033-3 2-s2.0-34248232601 (Pubitemid 46716789)
20. Wiseman S. M., Masoudi H., Niblock P., Turbin D., Rajput A., Hay J., Bugis S., Filipenko D., Huntsman D., Gilks B., Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Annals of Surgical Oncology 2007 14 2 719 729 10.1245/s10434-006- 9178-6 2-s2.0-33846647957 (Pubitemid 46175318)
21. Denaro N., Nigro C. L., Russi E. G., The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. Oncotargets and Therapy 2013 16 9 1231 1241
22. Deshpande H. A., Roman S., Sosa J. A., New targeted therapies and other advances in the management of anaplastic thyroid cancer. Current Opinion in Oncology 2013 25 1 44 49 10.1097/CCO.0b013e32835a448c 2-s2.0-84871971926
23. Guerra A., Di Crescenzo V., Garzi A., Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review. BMC Surgery 2013 8 13, supplement 2 S44
24. Li M., Milas M., Nasr C., Brainard J. A., Khan M. J., Burkey B. B., Scharpf J., Anaplastic thyroid cancer in young patients: a contemporary review. The American Journal of Otolaryngology 2013 34 6 636 640 10.1016/j.amjoto.2013. 07.008
25. Magro G., Perissinotto D., Schiappacassi M., Goletz S., Otto A., Müller E., Bisceglia M., Brown G., Ellis T., Grasso S., Colombatti A., Perris R., Proteomic and postproteomic characterization of keratan sulfate-glycanated isoforms of thyroglobulin and transferrin uniquely elaborated by papillary thyroid carcinomas. American Journal of Pathology 2003 163 1 183 196 10.1016/S0002-9440(10)63642-5 2-s2.0-0037631555 (Pubitemid 36759603)
26. Magro G., Schiappacassi M., Perissinotto D., Corsaro A., Borghese C., Belfiore A., Colombatti A., Grasso S., Botti C., Bombardieri E., Perris R., Differential expression of mucins 1-6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ. Journal of Pathology 2003 200 3 357 369 10.1002/path.1360 2-s2.0-0038348192 (Pubitemid 36827310)
27. Wreesmann V. B., Sieczka E. M., Socci N. D., Hezel M., Belbin T. J., Childs G., Patel S. G., Patel K. N., Tallini G., Prystowsky M., Shaha A. R., Kraus D., Shah J. P., Rao P. H., Ghossein R., Singh B., Genome-wide profiling of papillary thyroid cancer identities MUC1 as an independent prognostic marker. Cancer Research 2004 64 11 3780 3789 10.1158/0008-5472.CAN-03-1460 2-s2.0-2542632632 (Pubitemid 38697287)
28. Delys L., Detours V., Franc B., Thomas G., Bogdanova T., Tronko M., Libert F., Dumont J. E., Maenhaut C., Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene 2007 26 57 7894 7903 10.1038/sj.onc.1210588 2-s2.0-34548579392 (Pubitemid 350261783)
29. Rusinek D., Sylwia-Ulczok S., Jarzab B., Gene expression profile of human thyroid cancer in relation to its mutational status. Journal of Molecular Endocrinology 2011 47 3 R91 R103 10.1530/JME-11-0023 2-s2.0-84856353764
30. Lee J., Hwang J. A., Lee E. K., Recent progress of genome study for anaplastic thyroid cancer. Genomics & Informatics 2013 11 2 68 75
31. Hunt J. L., Tometsko M., LiVolsi V. A., Swalsky P., Finkelstein S. D., Barnes E. L., Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. The American Journal of Surgical Pathology 2003 27 12 1559 1564 10.1097/00000478-200312000- 00009 2-s2.0-0345293168 (Pubitemid 37486618)
32. Smallridge R. C., Marlow L. A., Copland J. A., Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocrine-Related Cancer 2009 16 1 17 44 10.1677/ERC-08-0154 2-s2.0-65549128212
33. Amico P., Lanzafame S., Li Destri G., Warthin tumor-like papillary thyroid carcinoma with a minor dedifferentiated component: report of a case with clinicopathologic considerations. Case Reports in Medicine 2010 2010 5 495281 10.1155/2010/495281
34. Ozaki O., Ito K., Mimura T., Sugino K., Ito K., Anaplastic transformation of papillary thyroid carcinoma in recurrent disease in regional lymph nodes: a histologic and immunohistochemical study. Journal of Surgical Oncology 1999 70 1 45 48 10.1002/(SICI)1096-9098(199901)70:1<45::AID-JSO8>3.0.CO;2-B (Pubitemid 29061994)
35. Wreesmann V. B., Ghossein R. A., Patel S. G., Harris C. P., Schnaser E. A., Shaha A. R., Michael Tuttle R., Shah J. P., Rao P. H., Singh B., Genome-wide appraisal of thyroid cancer progression. The American Journal of Pathology 2002 161 5 1549 1556 10.1016/S0002-9440(10)64433-1 2-s2.0-0036841090 (Pubitemid 35265515)
36. Nikiforov Y. E., Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocrine Pathology 2004 15 4 319 327 10.1385/EP:15:4:319 2-s2.0-13444311710 (Pubitemid 40208912)
37. Ruggeri R. M., Campenni A., Baldari S., Trimarchi F., Trovato M., What is new on thyroid cancer biomarkers. Biomarker Insights 2008 29 3 237 252 2-s2.0-43349098673 (Pubitemid 351658729)
38. O'Neill J. P., Shaha A. R., Anaplastic thyroid cancer. Oral Oncology 2013 49 7 702 706 10.1016/j.oraloncology.2013.03.440 2-s2.0-84879076365
39. Garcia-Rostan G., Zhao H., Camp R. L., Pollan M., Herrero A., Pardo J., Wu R., Carcangiu M. L., Costa J., Tallini G., Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal of Clinical Oncology 2003 21 17 3226 3235 10.1200/JCO.2003.10.130 2-s2.0-0141465066 (Pubitemid 46606254)
40. Nikiforov Y. E., Thyroid carcinoma: molecular pathways and therapeutic targets. Modern Pathology 2008 21 supplement 2 S37 S43 10.1038/modpathol.2008.10 2-s2.0-42549088683 (Pubitemid 351592770)
41. Nikiforova M. N., E Nikiforov Y., Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Review of Molecular Diagnostics 2008 8 1 83 95 10.1586/14737159.8.1.83 2-s2.0-38149036597
42. de Biase D., Visani M., Pession A., Tallini G., Molecular diagnosis of carcinomas of the thyroid gland. Frontiers in Bioscience 2014 6 1 14
43. Gómez Sáez J. M., Diagnostic and prognostic markers in differentiated thyroid cancer. Current Genomics 2011 12 8
44. Kim K. B., Cabanillas M. E., Lazar A. J., Williams M. D., Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 2013 23 10 1277 1283 10.1089/thy.2013.0057
45. Rosove M. H., Peddi P. F., Glaspy J. A., BRAF V600E inhibition in anaplastic thyroid cancer. The New England Journal of Medicine 2013 368 7 684 685 10.1056/NEJMc1215697 2-s2.0-84873641344
46. García-Rostán G., Costa A. M., Pereira-Castro I., Salvatore G., Hernandez R., Hermsem M. J. A., Herrero A., Fusco A., Cameselle-Teijeiro J., Santoro M., Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Research 2005 65 22 10199 10207 10.1158/0008-5472.CAN-04-4259 2-s2.0-28544452359 (Pubitemid 41743711)
47. Hou P., Liu D., Shan Y., Hu S., Studeman K., Condouris S., Wang Y., Trink A., El-Naggar A. K., Tallini G., Vasko V., Xing M., Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clinical Cancer Research 2007 13 4 1161 1170 10.1158/1078-0432.CCR-06- 1125 2-s2.0-33947284529 (Pubitemid 46424056)
48. Donghi R., Longoni A., Pilotti S., Michieli P., Della Porta G., Pierotti M. A., Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. Journal of Clinical Investigation 1993 91 4 1753 1760 10.1172/JCI116385 2-s2.0-0027215123 (Pubitemid 23127381)
49. Fagin J. A., Matsuo K., Karmakar A., Tang S.-., Koeffler H. P., High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. Journal of Clinical Investigation 1993 91 1 179 184 10.1172/JCI116168 2-s2.0-0027455042 (Pubitemid 23037270)
50. Quiros R. M., Ding H. G., Gattuso P., Prinz R. A., Xu X., Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 2005 103 11 2261 2268 10.1002/cncr.21073 2-s2.0-18844437226 (Pubitemid 40686569)
51. Sobrinho-Simões M., Máximo V., Rocha A. S., Trovisco V., Castro P., Preto A., Lima J., Soares P., Intragenic mutations in thyroid cancer. Endocrinology & Metabolism Clinics of North America 2008 37 2 333 362 10.1016/j.ecl.2008.02.004 2-s2.0-43849083525 (Pubitemid 351698087)
52. Moretti F., Nanni S., Farsetti A., Narducci M., Crescenzi M., Giuliacci S., Sacchi A., Pontecorvi A., Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. Journal of Clinical Endocrinology and Metabolism 2000 85 1 302 308 10.1210/jc.85.1.302 2-s2.0-0034458237 (Pubitemid 32268830)
53. Garcia-Rostan G., Tallini G., Herrero A., D'Aquila T. G., Carcangiu M. L., Rimm D. L., Frequent mutation and nuclear localization of β -catenin in anaplastic thyroid carcinoma. Cancer Research 1999 59 8 1811 1815 2-s2.0-0033561515 (Pubitemid 29186147)
54. Garcia-Rostan G., Camp R. L., Herrero A., Carcangiu M. L., Rimm D. L., Tallini G., Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. American Journal of Pathology 2001 158 3 987 996 10.1016/S0002-9440(10)64045-X 2-s2.0-0035108299 (Pubitemid 32221790)
55. Wiseman S. M., Masoudi H., Niblock P., Turbin D., Rajput A., Hay J., Filipenko D., Huntsman D., Gilks B., Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. American Journal of Surgery 2006 191 5 581 587 10.1016/j.amjsurg. 2006.02.005 2-s2.0-33646490738
56. Li Y., Zhang X., Polakiewicz R. D., Yao T., Comb M. J., HDAC6 is required for epidermal growth factor-induced β -catenin nuclear localization. Journal of Biological Chemistry 2008 283 19 12686 12690 10.1074/jbc.C700185200 2-s2.0-45149089913
57. Rossi E. D., Straccia P., Palumbo M., Stigliano E., Revelli L., Lombardi C. P., Santeusanio G., Pontecorvi A., Fadda G., Diagnostic and prognostic role of HBME-1, galectin-3, and β -catenin in poorly differentiated and anaplastic thyroid carcinomas. Applied Immunohistochemistry and Molecular Morphology 2013 21 3 237 241 10.1097/PAI.0b013e3182688d0f 2-s2.0-84877000331
58. Bartel D. P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 116 2 281 297 10.1016/S0092-8674(04)00045-5 2-s2.0-0347444723 (Pubitemid 38167318)
59. He L., Hannon G. J., MicroRNAs: small RNAs with a big role in gene regulation. Nature Reviews Genetics 2004 5 7 522 531 10.1038/nrg1379 2-s2.0-3042767202 (Pubitemid 38868508)
60. Hauptman N., Glavac D., MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer. Radiology and Oncology 2013 8 4 311 318
61. Sethi S., Ali S., Philip P. A., Sarkar F. H., Clinical advances in molecular biomarkers for cancer diagnosis and therapy. International Journal of Molecular Sciences 2013 14 7 14771 14784 10.3390/ijms140714771 2-s2.0-84880712727
62. Pallante P., Visone R., Ferracin M., Ferraro A., Berlingieri M. T., Troncone G., Chiappetta G., Liu C. G., Santoro M., Negrini M., Croce C. M., Fusco A., MicroRNA deregulation in human thyroid papillary carcinomas. Endocrine-Related Cancer 2006 13 2 497 508 10.1677/erc.1.01209 2-s2.0-33745077330 (Pubitemid 43886672)
63. Visone R., Pallante P., Vecchione A., Cirombella R., Ferracin M., Ferraro A., Volinia S., Coluzzi S., Leone V., Borbone E., Liu C.-., Petrocca F., Troncone G., Calin G. A., Scarpa A., Colato C., Tallini G., Santoro M., Croce C. M., Fusco A., Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 2007 26 54 7590 7595 10.1038/sj.onc.1210564 2-s2.0-36749001614 (Pubitemid 350207711)
64. Mitomo S., Maesawa C., Ogasawara S., Iwaya T., Shibazaki M., Yashima-Abo A., Kotani K., Oikawa H., Sakurai E., Izutsu N., Kato K., Komatsu H., Ikeda K., Wakabayashi G., Masuda T., Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Science 2008 99 2 280 286 10.1111/j.1349-7006.2007.00666.x 2-s2.0-38949168082 (Pubitemid 351228481)
65. Nikiforova M. N., Tseng G. C., Steward D., Diorio D., Nikiforov Y. E., MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. Journal of Clinical Endocrinology and Metabolism 2008 93 5 1600 1608 10.1210/jc.2007-2696 2-s2.0-43049180764 (Pubitemid 351656494)
66. Takakura S., Mitsutake N., Nakashima M., Namba H., Saenko V. A., Rogounovitch T. I., Nakazawa Y., Hayashi T., Ohtsuru A., Yamashita S., Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Science 2008 99 6 1147 1154 10.1111/j.1349-7006.2008.00800.x 2-s2.0-43549098845 (Pubitemid 351676626)
67. Volinia S., Calin G. A., Liu C. G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R. L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C. C., Croce C. M., A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America 2006 103 7 2257 2261 10.1073/pnas.0510565103 2-s2.0-33144490646 (Pubitemid 43271657)
68. Chiappetta G., Bandiera A., Berlingieri M. T., Visconti R., Manfioletti G., Battista S., Martinez-Tello F. J., Santoro M., Giancotti V., Fusco A., The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 1995 10 7 1307 1314 2-s2.0-0028970056
69. Berlingieri M. T., Pierantoni G. M., Giancotti V., Santoro M., Fusco A., Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 2002 21 19 2971 2980 10.1038/sj/onc/1205368 2-s2.0-0037007433 (Pubitemid 34522896)
70. Jhiang S. M., Sagartz J. E., Tong Q., Parker-thornburg J., Capen C. C., Cho J., Xing S., Ledent C., Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996 137 1 375 378 10.1210/en.137.1.375 2-s2.0-0029671246
71. Knauf J. A., Ma X., Smith E. P., Zhang L., Mitsutake N., Liao X., Refetoff S., Nikiforov Y. E., Fagin J. A., Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Research 2005 65 10 4238 4245 10.1158/0008-5472.CAN-05-0047 2-s2.0-20144372793 (Pubitemid 40775662)
72. Franco A. T., Malaguarnera R., Refetoff S., Liao X., Lundsmith E., Kimura S., Pritchard C., Marais R., Davies T. F., Weinstein L. S., Chen M., Rosen N., Ghossein R., Knauf J. A., Fagin J. A., Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proceedings of the National Academy of Sciences of the United States of America 2011 108 4 1615 1620 10.1073/pnas.1015557108 2-s2.0-79952180384
73. Kaneshige M., Kaneshige K., Zhu X., Dace A., Garrett L., Carter T. A., Kazlauskaite R., Pankratz D. G., Wynshaw-Boris A., Refetoff S., Weintraub B., Willingham M. C., Barlow C., Cheng S., Mice with a targeted mutation in the thyroid hormone β receptor gene exhibit impaired growth and resistance to thyroid hormone. Proceedings of the National Academy of Sciences of the United States of America 2000 97 24 13209 13214 10.1073/pnas.230285997 2-s2.0-12944311040
74. Suzuki H., Willingham M. C., Cheng S. Y., Mice with a mutation in the thyroid hormone receptor β gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 2002 12 11 963 969 10.1089/105072502320908295 2-s2.0-6444245375 (Pubitemid 35404130)
75. Miller K. A., Yeager N., Baker K., Liao X., Refetoff S., Cristofano A. D. I., Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Research 2009 69 8 3689 3694 10.1158/0008-5472.CAN-09-0024 2-s2.0-65949117244
76. Antico-Arciuch V. G., Dima M., Liao X.-H., Refetoff S., Di Cristofano A., Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. Oncogene 2010 29 42 5678 5686 10.1038/onc.2010.308 2-s2.0-77958510966
77. Antico Arciuch V. G., Russo M. A., Dima M., Kang K. S., Dasrath F., Liao X., Refetoff S., Montagna C., Di Cristofano A., Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget 2011 2 12 1109 1126 2-s2.0-84865273469
78. Nehs M. A., Nucera C., Nagarkatti S. S., Sadow P. M., Morales-Garcia D., Hodin R. A., Parangi S., Late intervention with anti-BRAF V600E therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology 2012 153 2 985 994 10.1210/en.2011-1519 2-s2.0-84856112428
79. Tsai J., Lee J. T., Wang W., Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America 2008 105 8 3041 3046 10.1073/pnas.0711741105 (Pubitemid 351723664)
80. Braga-Basaria M., Ringel M. D., Clinical review 158: beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2003 88 5 1947 1960 10.1210/jc.2002-021863 2-s2.0-0038707599 (Pubitemid 36549861)
81. Durante C., Puxeddu E., Ferretti E., Morisi R., Moretti S., Bruno R., Barbi F., Avenia N., Scipioni A., Verrienti A., Tosi E., Cavaliere A., Gulino A., Filetti S., Russo D., Brief report: BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. Journal of Clinical Endocrinology and Metabolism 2007 92 7 2840 2843 10.1210/jc.2006-2707 2-s2.0-34447134910 (Pubitemid 47037399)
82. Riesco-Eizaguirre G., Rodríguez I., de La Vieja A., Costamagna E., Carrasco N., Nistal M., Santisteban P., The BRAFV600E oncogene induces transforming growth factor β secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Research 2009 69 21 8317 8325 10.1158/0008-5472.CAN-09-1248 2-s2.0-70350554104
83. Kleiman D. A., Buitrago D., Crowley M. J., Beninato T., Veach A. J., Zanzonico P. B., Jin M., Fahey T. J. III, Zarnegar R., Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing. Journal of Surgical Research 2013 182 1 85 93 10.1016/j.jss.2012.08.053 2-s2.0-84876667088
84. Sewell W., Reeb A., Lin R. Y., An orthotopic mouse model of anaplastic thyroid carcinoma. Journal of Visualized Experiments 2013 74 10.3791/50097
85. McFadden D. G., Vernon A., Santiago P. M., p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proceedings of the National Academy of Sciences of the United States of America 2014 111 16 E1600 E1609
86. Antonello Z. A., Nucera C., Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF. Oncogene 2013 10.1038/onc.2013.544
87. Daniels T. R., Delgado T., Rodriguez J. A., Helguera G., Penichet M. L., The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clinical Immunology 2006 121 2 144 158 10.1016/j.clim.2006.06.010 2-s2.0-33750008791 (Pubitemid 44592578)
88. Daniels T. R., Delgado T., Helguera G., Penichet M. L., The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clinical Immunology 2006 121 2 159 176 10.1016/j.clim.2006.06.006 2-s2.0-33750019824 (Pubitemid 44572972)
89. Daniels T. R., Bernabeu E., Rodríguez J. A., The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochimica et Biophysica Acta 2012 1820 3 291 317
90. Pantopoulos K., Iron metabolism and the IRE/IRP regulatory system: An update. Annals of the New York Academy of Sciences 2004 1012 1 13 10.1196/annals.1306.001 2-s2.0-1842608845 (Pubitemid 38453511)
91. Magro G., Cataldo I., Amico P., Torrisi A., Vecchio G. M., Parenti R., Asioli S., Recupero D., D'Agata V., Mucignat M. T., Perris R., Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target. Thyroid 2011 21 3 267 277 10.1089/thy.2010.0173 2-s2.0-79952414715
92. Higashi T., Watanabe Y., Yamaguchi M., Hisada T., Mimura T., Ito K., Allison J. R., The relationships between the Ga-67 uptake and nuclear DNA Feulgen content in thyroid tumors: concise communication. Journal of Nuclear Medicine 1982 23 11 988 992 2-s2.0-0020416883 (Pubitemid 13254950)
93. Senga O., Miyakawa M., Shirota H., Makiuchi M., Yano K., Miyazawa M., Takizawa M., Comparison of Tl-201 chloride and Ga-67 citrate scintigraphy in the diagnosis of thyroid tumor: concise communication. Journal of Nuclear Medicine 1982 23 3 225 228 2-s2.0-0020084578 (Pubitemid 12185176)
94. Chitambar C. R., Zivkovic Z., Uptake of gallium-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin- independent mechanisms. Cancer Research 1987 47 15 3929 3934 2-s2.0-0023262160 (Pubitemid 17108447)
95. Chitambar C. R., Wereley J. P., Matsuyama S., Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition. Molecular Cancer Therapeutics 2006 5 11 2834 2843 10.1158/1535-7163.MCT-06-0285 2-s2.0-33845208145 (Pubitemid 44849010)
96. Chitambar C. R., Purpi D. P., Woodliff J., Yang M., Wereley J. P., Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate. Journal of Pharmacology and Experimental Therapeutics 2007 322 3 1228 1236 10.1124/jpet.107.126342 2-s2.0-34548075249 (Pubitemid 47295794)
97. Kondo K., Noguchi M., Mukai K., Matsuno Y., Sato Y., Shimosato Y., Monden Y., Transferrin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis. Chest 1990 97 6 1367 1371 10.1378/chest.97.6.1367 2-s2.0-0025327937 (Pubitemid 20185681)
98. Tsuchiya Y., Nakao A., Komatsu T., Yamamoto M., Shimokata K., Relationship between gallium 67 citrate scanning and transferrin receptor expression in lung diseases. Chest 1992 102 2 530 534 10.1378/chest.102.2.530 2-s2.0-0026782138
99. Högemann-Savellano D., Bost E., Blondet C., Sato F., Abe T., Josephson L., Weissleder R., Gaudet J., Sgroi D., Peters P. J., Basilion J. P., The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 2003 5 6 495 506 10.1016/S1476-5586(03)80034-9 2-s2.0-9144229333 (Pubitemid 38045087)
100. Chikh Z., Ha-Duong N. T., Miquel G., El Hage Chahine J., Gallium uptake by transferrin and interaction with receptor 1. Journal of Biological Inorganic Chemistry 2007 12 1 90 100 10.1007/s00775-006-0169-7 2-s2.0-33845368917 (Pubitemid 44885512)
101. Chitambar C. R., Gallium-containing anticancer compounds. Future Medicinal Chemistry 2012 4 10 1257 1272 10.4155/fmc.12.69 2-s2.0-84863903473
102. Gómez-Ruiz S., Gallego B., Kaluderović M. R., Kommera H., Hey-Hawkins E., Paschke R., Kaluderović G. N., Novel gallium(III) complexes containing phthaloyl derivatives of neutral aminoacids with apoptotic activity in cancer cells. Journal of Organometallic Chemistry 2009 694 14 2191 2197 10.1016/j.jorganchem.2009.02.027 2-s2.0-65749100628
103. Chitambar C. R., Seligman P. A., Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells. Mechanisms responsible for the specific cytotoxicity of transferrin-gallium. Journal of Clinical Investigation 1986 78 6 1538 1546 10.1172/JCI112746 2-s2.0-0022839492 (Pubitemid 17219517)
104. Bernstein L. R., Mechanisms of therapeutic activity for gallium. Pharmacological Reviews 1998 50 4 665 682 2-s2.0-0032445152 (Pubitemid 29028814)
105. Rodríguez J. A., Luria-Pérez R., López-Valdés H. E., Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells. Leukemia and Lymphoma 2011 52 11 2169 2178 10.3109/10428194.2011.596964
106. Daniels T. R., Ortiz-Sánchez E., Luria-Pérez R., Quintero R., Helguera G., Bonavida B., Martínez-Maza O., Penichet M. L., An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies. Journal of Immunotherapy 2011 34 6 500 508 10.1097/CJI.0b013e318222ffc8
107. Ng P. P., Cruz J. S. D., Sorour D. N., Stinebaugh J. M., Shin S., Shin D. S., Morrison S. L., Penichet M. L., An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2002 99 16 10706 10711 10.1073/pnas.162362999 2-s2.0-0036678172
108. Jones D. T., Trowbridge I. S., Harris A. L., Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate. Cancer Research 2006 66 5 2749 2756 10.1158/0008-5472.CAN-05-3857 2-s2.0-33645066360
109. Brooks D., Taylor C., Dos Santos B., Linden H., Houghton A., Hecht T. T., Kornfeld S., Taetle R., Phase Ia trial of murine immunoglobulin a antitransferrin receptor antibody 42/6 1. Clinical Cancer Research 1995 1 11 1259 1265 2-s2.0-0028809381
110. Qing Y., Shuo W., Zhihua W., Huifen Z., Ping L., Lijiang L., Xiaorong Z., Liming C., Daiwen X., Yu H., Wei X., Min F., Zuohua F., Guanxin S., The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor. Cancer Immunology, Immunotherapy 2006 55 9 1111 1121 10.1007/s00262-005-0105-7 2-s2.0-33744464256 (Pubitemid 43800726)
111. Callens C., Moura I. C., Lepelletier Y., Coulon S., Renand A., Dussiot M., Ghez D., Benhamou M., Monteiro R. C., Bazarbachi A., Hermine O., Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia 2008 22 1 42 48 10.1038/sj.leu.2404958 2-s2.0-38349170646
112. Rodríguez J. A., Luria-Pérez R., López-Valdés H. E., Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells. Leukemia & Lymphoma 2011 52 11 2169 2178 10.3109/10428194.2011.596964
113. Daniels-Wells T. R., Helguera G., Rodríguez J. A., Leoh L. S., Erb M. A., Diamante G., Casero D., Pellegrini M., Martínez-Maza O., Penichet M. L., Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. Toxicology In Vitro 2013 27 1 220 231 10.1016/j.tiv.2012.10.006 2-s2.0-84869427890
114. Leoh L. S., Morizono K., Kershaw K. M., Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. Journal of Gene Medicine 2014 16 11 27
115. Davis M. E., Zuckerman J. E., Choi C. H. J., Seligson D., Tolcher A., Alabi C. A., Yen Y., Heidel J. D., Ribas A., Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010 464 7291 1067 1070 10.1038/nature08956 2-s2.0-77951132901
116. Perris R., Borghese C., Magro G., Pitfalling in nanomedical targeting of melanoma: a "clinical" case of misdelivered RNAi. Pigment Cell and Melanoma Research 2011 24 5 980 982 10.1111/j.1755-148X.2011.00888.x 2-s2.0-80053923783